The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
The BRAF–MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells
Open accessAbstract
The mitogen-activated protein kinase (MAPK) pathway is frequently activated in human cancers, leading to malignant phenotypes such as autonomous cellular proliferation. Here, we demonstrate a novel role of the activated MAPK pathway in immune evasion by melanoma cells with the mutation of BRAF, which encodes a MAPKKs, (BRAFV600E). MEK inhibitor U0126 or RNA interference (RNAi) for BRAFV600E decreased production of the immunosuppressive soluble factors interleukin (IL)-10, VEGF, or IL-6 from melanoma cells to levels comparable to those after signal transducer and activator of transcription (STAT)3 inactivation. The suppressive activity of the culture supernatants from the melanoma cells on the production of inflammatory cytokines IL-12 and tumor necrosis factor α by dendritic cells upon lipopolysaccharide stimulation was markedly reduced after transduction with BRAFV600E RNAi, comparable to the effects observed with STAT3 RNAi transduction. No additive or synergistic effects were observed by the simultaneous transduction of RNAi for both BRAFV600E and STAT3. Furthermore, specific DNA binding and transcriptional activity of STAT3 were not affected by down-regulation of the MAPK signaling with the BRAF RNAi. These results indicate that the MAPK signal, along with the STAT3 signal, is essential for immune evasion by human melanomas that have constitutively active MAPK signaling and is a potential molecular target for overcoming melanoma cell evasion of the immune system.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
Immunosuppressive networks in the tumour environment and their therapeutic relevance
Zou, W. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1586 · Cited by 2,057
Wen, Z., Zhong, Z., & Darnell, J. E. (1995) · Cell · doi:10.1016/0092-8674(95)90311-9 · Cited by 1,974
Rosenberg, S. A., Yang, J. C., Schwartzentruber, D. J., Hwu, P., Marincola, F. M., Topalian, S. L., Restifo, N. P., Dudley, M. E., Schwarz, S. L., Spiess, P. J., et al. (1998) · Nature Medicine · doi:10.1038/nm0398-321 · Cited by 1,784
Self-citationMarincola, F. M., Jaffee, E. M., Hicklin, D. J., & Ferrone, S. (1999) · Advances in Immunology · doi:10.1016/s0065-2776(08)60911-6 · Cited by 1,174
Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells
Wang, T., Niu, G., Kortylewski, M., Burdelya, L., Shain, K., Zhang, S., Bhattacharya, R., Gabrilovich, D., Heller, R., Coppola, D., et al. (2004) · Nature Medicine · doi:10.1038/nm976 · Cited by 1,155
Kawakami, Y., Eliyahu, S., Delgado, C. H., Robbins, P. F., Rivoltini, L., Topalian, S. L., Miki, T., & Rosenberg, S. A. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.9.3515 · Cited by 1,092
Self-citationMechanisms and functional significance of tumour-induced dendritic-cell defects
Gabrilovich, D. (2004) · Nature Reviews Immunology · doi:10.1038/nri1498 · Cited by 1,024
Kawakami, Y., Eliyahu, S., Delgado, C. H., Robbins, P. F., Sakaguchi, K., Appella, E., Yannelli, J. R., Adema, G. J., Miki, T., & Rosenberg, S. A. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.14.6458 · Cited by 914
Self-citationChung, J., Uchida, E., Grammer, T. C., & Blenis, J. (1997) · Molecular and Cellular Biology · doi:10.1128/mcb.17.11.6508 · Cited by 620
Cited by
Mantovani, A., Allavena, P., Sica, A., & Balkwill, F. (2008) · Nature · doi:10.1038/nature07205 · Cited by 11,399
Understanding the tumor immune microenvironment (TIME) for effective therapy
Binnewies, M., Roberts, E. W., Kersten, K., Chan, V., Fearon, D. F., Merad, M., Coussens, L. M., Gabrilovich, D. I., Ostrand-Rosenberg, S., Hedrick, C. C., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0014-x · Cited by 6,145
STATs in cancer inflammation and immunity: a leading role for STAT3
Yu, H., Pardoll, D., & Jove, R. (2009) · Nature reviews. Cancer · doi:10.1038/nrc2734 · Cited by 4,383
Approaches to treat immune hot, altered and cold tumours with combination immunotherapies
Galon, J., & Bruni, D. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0007-y · Cited by 3,409
Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy
Topalian, S. L., Taube, J. M., Anders, R. A., & Pardoll, D. M. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.36 · Cited by 2,733
Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment
Yu, H., Kortylewski, M., & Pardoll, D. (2007) · Nature Reviews Immunology · doi:10.1038/nri1995 · Cited by 1,804
Adoptive immunotherapy for cancer: harnessing the T cell response
Restifo, N. P., Dudley, M. E., & Rosenberg, S. A. (2012) · Nature Reviews Immunology · doi:10.1038/nri3191 · Cited by 1,688
Combining immunotherapy and targeted therapies in cancer treatment
Vanneman, M., & Dranoff, G. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3237 · Cited by 1,586
Tumour-intrinsic resistance to immune checkpoint blockade
Kalbasi, A., & Ribas, A. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-019-0218-4 · Cited by 1,486
Zitvogel, L., Galluzzi, L., Smyth, M. J., & Kroemer, G. (2013) · Immunity · doi:10.1016/j.immuni.2013.06.014 · Cited by 870
Roh, W., Chen, P.-L., Reuben, A., Spencer, C. N., Prieto, P. A., Miller, J. P., Gopalakrishnan, V., Wang, F., Cooper, Z. A., Reddy, S. M., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aah3560 · Cited by 859
The complex role of tumor-infiltrating macrophages
Christofides, A., Strauss, L., Yeo, A., Cao, C., Charest, A., & Boussiotis, V. A. (2022) · Nature Immunology · doi:10.1038/s41590-022-01267-2 · Cited by 849
Turning cold tumors into hot tumors by improving T-cell infiltration
Liu, Y.-T., & Sun, Z.-J. (2021) · Theranostics · doi:10.7150/thno.58390 · Cited by 827
Regulation of PD-L1: a novel role of pro-survival signalling in cancer.
Chen, J., Jiang, C. C., Jin, L., & Zhang, X. D. (2016) · Annals of Oncology · doi:10.1093/annonc/mdv615 · Cited by 767
Chen, D. S., Irving, B. A., & Hodi, F. S. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1362 · Cited by 654
Selective BRAF Inhibitors Induce Marked T-cell Infiltration into Human Metastatic Melanoma
Wilmott, J. S., Long, G. V., Howle, J. R., Haydu, L. E., Sharma, R. N., Thompson, J. F., Kefford, R. F., Hersey, P., & Scolyer, R. A. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2479 · Cited by 652
Stat3 mediates myeloid cell–dependent tumor angiogenesis in mice
Kujawski, M., Kortylewski, M., Lee, H., Herrmann, A., Kay, H., & Yu, H. (2008) · Journal of Clinical Investigation · doi:10.1172/jci35213 · Cited by 581
Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF V600E melanoma
Hu-Lieskovan, S., Mok, S., Homet Moreno, B., Tsoi, J., Robert, L., Goedert, L., Pinheiro, E. M., Koya, R. C., Graeber, T. G., Comin-Anduix, B., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa4691 · Cited by 563
McDermott, D. F., Sosman, J. A., Sznol, M., Massard, C., Gordon, M. S., Hamid, O., Powderly, J. D., Infante, J. R., Fassò, M., Wang, Y. V., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.7421 · Cited by 557
PD‐1/PD‐L1 immune checkpoint: Potential target for cancer therapy
Dermani, F. K., Samadi, P., Rahmani, G., Kohlan, A. K., & Najafi, R. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.27172 · Cited by 504
Pathways connecting inflammation and cancer
Allavena, P., Garlanda, C., Borrello, M. G., Sica, A., & Mantovani, A. (2008) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2008.01.003 · Cited by 437
Managing Immune Checkpoint-Blocking Antibody Side Effects
Postow, M. A. (2015) · American Society of Clinical Oncology Educational Book · doi:10.14694/edbook_am.2015.35.76 · Cited by 403
STAT3-induced S1PR1 expression is crucial for persistent STAT3 activation in tumors
Lee, H., Deng, J., Kujawski, M., Yang, C., Liu, Y., Herrmann, A., Kortylewski, M., Horne, D., Somlo, G., Forman, S., et al. (2010) · Nature Medicine · doi:10.1038/nm.2250 · Cited by 395
Liu, C., Peng, W., Xu, C., Lou, Y., Zhang, M., Wargo, J. A., Chen, J. Q., Li, H. S., Watowich, S. S., Yang, Y., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1626 · Cited by 381
“Do We Know Jack” About JAK? A Closer Look at JAK/STAT Signaling Pathway
Bousoik, E., & Montazeri Aliabadi, H. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00287 · Cited by 376
Cancer prevention and therapy through the modulation of the tumor microenvironment
Casey, S. C., Amedei, A., Aquilano, K., Azmi, A. S., Benencia, F., Bhakta, D., Bilsland, A. E., Boosani, C. S., Chen, S., Ciriolo, M. R., et al. (2015) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2015.02.007 · Cited by 372
B cells sustain inflammation and predict response to immune checkpoint blockade in human melanoma
Griss, J., Bauer, W., Wagner, C., Simon, M., Chen, M., Grabmeier-Pfistershammer, K., Maurer-Granofszky, M., Roka, F., Penz, T., Bock, C., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-12160-2 · Cited by 369
Clinical Development of BRAF plus MEK Inhibitor Combinations
Subbiah, V., Baik, C., & Kirkwood, J. M. (2020) · Trends in Cancer · doi:10.1016/j.trecan.2020.05.009 · Cited by 344
The role of STAT3 in leading the crosstalk between human cancers and the immune system
Wang, Y., Shen, Y., Wang, S., Shen, Q., & Zhou, X. (2018) · Cancer Letters · doi:10.1016/j.canlet.2017.12.003 · Cited by 340
Tumor-associated Macrophages (TAM) and Inflammation in Colorectal Cancer
Erreni, M., Mantovani, A., & Allavena, P. (2011) · Cancer Microenvironment · doi:10.1007/s12307-010-0052-5 · Cited by 325
Wang, X., Yang, L., Huang, F., Zhang, Q., Liu, S., Ma, L., & You, Z. (2017) · Immunology Letters · doi:10.1016/j.imlet.2017.02.006 · Cited by 324
Proteomics of Melanoma Response to Immunotherapy Reveals Mitochondrial Dependence
Harel, M., Ortenberg, R., Varanasi, S. K., Mangalhara, K. C., Mardamshina, M., Markovits, E., Baruch, E. N., Tripple, V., Arama-Chayoth, M., Greenberg, E., et al. (2019) · Cell · doi:10.1016/j.cell.2019.08.012 · Cited by 324
Khalili, J. S., Liu, S., Rodríguez-Cruz, T. G., Whittington, M., Wardell, S., Liu, C., Zhang, M., Cooper, Z. A., Frederick, D. T., Li, Y., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1632 · Cited by 301
Raf kinases in cancer–roles and therapeutic opportunities
Maurer, G., Tarkowski, B., & Baccarini, M. (2011) · Oncogene · doi:10.1038/onc.2011.160 · Cited by 292
Interleukin 10 in the tumor microenvironment: a target for anticancer immunotherapy
Sato, T., Terai, M., Tamura, Y., Alexeev, V., Mastrangelo, M. J., & Selvan, S. R. (2011) · Immunologic Research · doi:10.1007/s12026-011-8262-6 · Cited by 286
MAPK signaling in inflammation-associated cancer development
Huang, P., Han, J., & Hui, L. (2010) · Protein & Cell · doi:10.1007/s13238-010-0019-9 · Cited by 273
Therapeutically Increasing MHC-I Expression Potentiates Immune Checkpoint Blockade
Gu, S. S., Zhang, W., Wang, X., Jiang, P., Traugh, N., Li, Z., Meyer, C., Stewig, B., Xie, Y., Bu, X., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0812 · Cited by 273
The Mitochondrial Chaperone TRAP1 Promotes Neoplastic Growth by Inhibiting Succinate Dehydrogenase
Sciacovelli, M., Guzzo, G., Morello, V., Frezza, C., Zheng, L., Nannini, N., Calabrese, F., Laudiero, G., Esposito, F., Landriscina, M., et al. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.04.019 · Cited by 264
Yang, L., Li, A., Lei, Q., & Zhang, Y. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0804-8 · Cited by 215
Molecular pathways in cancer-related inflammation
Del Prete, A., Allavena, P., Santoro, G., Fumarulo, R., Corsi, M. M., & Mantovani, A. (2011) · Biochemia Medica · doi:10.11613/bm.2011.036 · Cited by 181
Briere, D. M., Li, S., Calinisan, A., Sudhakar, N., Aranda, R., Hargis, L., Peng, D. H., Deng, J., Engstrom, L. D., Hallin, J., et al. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0462 · Cited by 168
Purity and yield of melanoma exosomes are dependent on isolation method
La Shu, S., Yang, Y., Allen, C. L., Hurley, E., Tung, K. H., Minderman, H., Wu, Y., & Ernstoff, M. S. (2020) · Journal of Extracellular Vesicles · doi:10.1080/20013078.2019.1692401 · Cited by 141
Combination of Immunotherapy With Targeted Therapy: Theory and Practice in Metastatic Melanoma
Yu, C., Liu, X., Yang, J., Zhang, M., Jin, H., Ma, X., & Shi, H. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00990 · Cited by 126
Kortylewski, M., Kujawski, M., Herrmann, A., Yang, C., Wang, L., Liu, Y., Salcedo, R., & Yu, H. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3031 · Cited by 122
“immunosuppression in the tumor microenvironment by inhibiting the expression of Th1 immunostimulatory molecules and promoting the expression of several immunosuppressive factors (9, 24).”
PTEN functions as a melanoma tumor suppressor by promoting host immune response
Dong, Y., Richards, J.-A., Gupta, R., Aung, P. P., Emley, A., Kluger, Y., Dogra, S. K., Mahalingam, M., & Wajapeyee, N. (2014) · Oncogene · doi:10.1038/onc.2013.409 · Cited by 113
Ferrari de Andrade, L., Ngiow, S. F., Stannard, K., Rusakiewicz, S., Kalimutho, M., Khanna, K. K., Tey, S.-K., Takeda, K., Zitvogel, L., Martinet, L., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-1339 · Cited by 105
Huang, W.-L., Yeh, H.-H., Lin, C.-C., Lai, W.-W., Chang, J.-Y., Chang, W.-T., & Su, W.-C. (2010) · Molecular Cancer · doi:10.1186/1476-4598-9-309 · Cited by 86
Lelliott, E. J., McArthur, G. A., Oliaro, J., & Sheppard, K. E. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.661737 · Cited by 65
Solís-Martínez, R., Cancino-Marentes, M., Hernández-Flores, G., Ortiz-Lazareno, P., Mandujano-Álvarez, G., Cruz-Gálvez, C., Sierra-Díaz, E., Rodríguez-Padilla, C., Jave-Suárez, L. F., Aguilar-Lemarroy, A., et al. (2018) · Immunology Letters · doi:10.1016/j.imlet.2018.02.009 · Cited by 47
PD‐L1 expression in melanocytic lesions does not correlate with the BRAF V600E mutation
Rodić, N., Anders, R. A., Eshleman, J. R., Lin, M.-T., Xu, H., Kim, J. H., Beierl, K., Chen, S., Luber, B. S., Wang, H., et al. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0145 · Cited by 46
Noji, R., Tohyama, K., Nakamura, S., Naito, T., Oikawa, Y., Kuroshima, T., Tomioka, H., Michi, Y., Ikeda, S., Asakage, T., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms26010235 · Cited by 11
“BRAF mutations, especially those that activate the MAPK pathway [20,21], can increase tumor immunogenicity and enhance T-cell infiltration, potentially sensitizing tumors to ICIs [22].”
Tumor-stroma interactions in tumorigenesis lessons from stem cell biology
Friedrich, K. (2012) · Frontiers in Bioscience · doi:10.2741/e509 · Cited by 10
Recruiting Immunity for the Fight against Colorectal Cancer: Current Status and Challenges
Al-Hujaily, E. M., Al-Sowayan, B. S., Alyousef, Z., Uddin, S., & Alammari, F. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232213696 · Cited by 6
Metadata
- Authors
- Sumimoto, H., Imabayashi, F., Iwata, T., & Kawakami, Y.
- Venue
- The Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2006-06-26
- Volume
- 203
- Issue
- 7
- Pages
- 1651-1656
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- OpenAlex
- W2122037714
- Cited by
- 698
- References
- 18
- FWCI
- 6.26
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.